EMERGENT BIOSOLUTIONS INC. Prepaid Expense and Other Assets, Current
EMERGENT BIOSOLUTIONS INC. (EBS) had Prepaid Expense and Other Assets, Current of $25.40 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-06
- 2026-06-30: Prepaid Expense and Other Assets, Current $25.40M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $26.90M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $25.80M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $25.60M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $25.40M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $26.90M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $25.80M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $25.60M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $24.00M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $30.20M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $26.90M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $61.00M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $36.00M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $36.50M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $47.90M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $62.40M 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $44.70M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $41.70M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $57.90M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $139.90M 10-Q · filed 2023-12-11 | |
| 2022-06-30 | $125.40M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $81.80M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $70.20M 10-K/A · filed 2023-12-11 | $70.30M 10-K · filed 2022-02-25 |
| 2021-09-30 | $88.30M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $66.10M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $42.20M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $36.50M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $77.40M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $32.10M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $24.10M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $25.00M 10-K · filed 2021-02-19 | $20.40M 10-K · filed 2020-02-25 |
| 2019-09-30 | $49.20M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $65.00M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $58.60M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $31.50M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $20.05M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $21.17M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $27.67M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $17.20M 10-K · filed 2019-02-22 | $17.16M 10-K · filed 2018-02-23 |
| 2017-09-30 | $15.75M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $14.96M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $13.41M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $16.23M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $18.44M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $22.05M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $25.61M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $18.46M 10-K · filed 2017-02-28 | $21.54M 10-K · filed 2016-02-29 |
| 2015-09-30 | $22.75M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $21.60M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $24.42M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $24.10M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $26.48M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $16.34M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $14.98M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $12.90M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $13.18M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $11.20M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $9.70M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $9.21M 10-K · filed 2014-03-10 | |
| 2012-09-30 | $9.76M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $7.49M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $7.91M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $8.28M 10-K · filed 2013-03-08 | |
| 2011-09-30 | $9.03M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $7.74M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $8.81M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |